Xiaoxi Yao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2349829/publications.pdf

Version: 2024-02-01

81	5,424	126708	85405
papers	citations	33 h-index	71 g-index

82	82	82	7083
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cardiovascular Disease Screening in Women: Leveraging Artificial Intelligence and Digital Tools. Circulation Research, 2022, 130, 673-690.	2.0	29
2	Artificial intelligenceâ€"electrocardiography to detect atrial fibrillation: trend of probability before and after the first episode. European Heart Journal Digital Health, 2022, 3, 228-235.	0.7	4
3	Artificial Intelligenceâ€"Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts. Mayo Clinic Proceedings, 2022, 97, 871-880.	1.4	6
4	Bringing context and nuance to risk prediction by incorporating social determinants of health. European Journal of Preventive Cardiology, 2022, , .	0.8	0
5	Generalizability of the EASTâ€AFNET 4 Trial: Assessing Outcomes of Early Rhythmâ€Control Therapy in Patients With Atrial Fibrillation. Journal of the American Heart Association, 2022, 11, .	1.6	14
6	Effect of hospital-at-home vs. traditional brick-and-mortar hospital care in acutely ill adults: study protocol for a pragmatic randomized controlled trial. Trials, 2022, 23, .	0.7	3
7	The Impact of Antifungal Prophylaxis in Lung Transplant Recipients. Annals of the American Thoracic Society, 2021, 18, 468-476.	1.5	10
8	Proprotein convertase subtilisin/kexin type 9 inhibitor utilization and low-density lipoprotein-cholesterol control in familial hypercholesterolemia. Journal of Clinical Lipidology, 2021, 15, 339-346.	0.6	2
9	Smart Wearables for Cardiac Monitoringâ€"Real-World Use beyond Atrial Fibrillation. Sensors, 2021, 21, 2539.	2.1	63
10	Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 286-297.	1.2	3
11	Artificial intelligenceâ€"enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial. Nature Medicine, 2021, 27, 815-819.	15.2	154
12	Long-Term Clinical Outcomes of Underdosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Atrial Flutter. American Journal of Medicine, 2021, 134, 788-796.	0.6	25
13	Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine use. Endocrine, 2021, 74, 592-602.	1.1	2
14	Cost Effectiveness of an Electrocardiographic Deep Learning Algorithm to Detect Asymptomatic Left Ventricular Dysfunction. Mayo Clinic Proceedings, 2021, 96, 1835-1844.	1.4	15
15	Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2021, 18, 1121-1128.	1.5	37
16	Batch enrollment for an artificial intelligence-guided intervention to lower neurologic events in patients with undiagnosed atrial fibrillation: rationale and design of a digital clinical trial. American Heart Journal, 2021, 239, 73-79.	1.2	21
17	Artificial Intelligence-Enabled ECG to Identify Silent Atrial Fibrillation in Embolic Stroke of Unknown Source. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105998.	0.7	19
18	Risk of Gastrointestinal Bleeding Increases With Combinations of Antithrombotic Agents and Patient Age. Clinical Gastroenterology and Hepatology, 2020, 18, 337-346.e19.	2.4	30

#	Article	IF	Citations
19	ECG AI-Guided Screening for Low Ejection Fraction (EAGLE): Rationale and design of a pragmatic cluster randomized trial. American Heart Journal, 2020, 219, 31-36.	1.2	50
20	Comparative Effectiveness of Sacubitril-ValsartanÂVersus ACE/ARB Therapy in Heart Failure With ReducedÂEjection Fraction. JACC: Heart Failure, 2020, 8, 43-54.	1.9	40
21	Clinical trial design data for electrocardiogram artificial intelligence-guided screening for low ejection fraction (EAGLE). Data in Brief, 2020, 28, 104894.	0.5	9
22	Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006515.	0.9	20
23	Long-Term Outcomes of Acute Myocardial Infarction With Concomitant Cardiogenic Shock and Cardiac Arrest. American Journal of Cardiology, 2020, 133, 15-22.	0.7	22
24	Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels. JAMA Network Open, 2020, 3, e2017645.	2.8	18
25	An AI-ECG algorithm for atrial fibrillation risk: steps towards clinical implementation â€“ Authors' reply. Lancet, The, 2020, 396, 236-237.	6.3	5
26	Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016. JAMA Network Open, 2020, 3, e2025505.	2.8	63
27	Artificial Intelligenceâ€“Electrocardiography to Predict Incident Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e009355.	2.1	68
28	Is Atrial Fibrillation Management as Simple as ABC?. Journal of the American Heart Association, 2020, 9, e016739.	1.6	1
29	Finding Order in Chaos. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006650.	0.9	1
30	Generalizability of the CASTLE-AF trial: Catheter ablation for patients with atrial fibrillation and heart failure in routine practice. Heart Rhythm, 2020, 17, 1057-1065.	0.3	54
31	How Will Machine Learning Inform the Clinical Care of Atrial Fibrillation?. Circulation Research, 2020, 127, 155-169.	2.0	35
32	Assessing and Mitigating Bias in Medical Artificial Intelligence. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007988.	2.1	116
33	NOAC dosing and monitoring: really as simple as it seems?. Heart, 2020, 106, 321-322.	1.2	3
34	Safety and Efficacy of Oral Anticoagulants for Atrial Fibrillation in Patients After Bariatric Surgery. American Journal of Cardiology, 2020, 136, 76-80.	0.7	6
35	Catheter-related complications and mortality of atrial fibrillation ablation following introduction of contact force-sensing technology. BMJ Surgery, Interventions, and Health Technologies, 2020, 2, e000058.	0.6	2
36	Abstract 14368: Artificial Intelligence-Electrocardiography to Predict Time to Atrial Fibrillation: An Analysis of Mayo Clinic Study of Aging. Circulation, 2020, 142, .	1.6	0

#	Article	IF	Citations
37	Variation in treatment practices for subclinical hypothyroidism in pregnancy: US national assessment. Journal of Clinical Endocrinology and Metabolism, 2019, , .	1.8	11
38	An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet, The, 2019, 394, 861-867.	6.3	794
39	Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association. Circulation, 2019, 140, e944-e963.	1.6	105
40	Evolution of the American College of Cardiology and American Heart Association Cardiology Clinical Practice Guidelines: A 10â€Year Assessment. Journal of the American Heart Association, 2019, 8, e012065.	1.6	8
41	Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 168-174.	2.5	102
42	Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2305-2314.	1.8	24
43	Atrial fibrillation ablation in practice: assessing CABANA generalizability. European Heart Journal, 2019, 40, 1257-1264.	1.0	105
44	Prospective validation of a deep learning electrocardiogram algorithm for the detection of left ventricular systolic dysfunction. Journal of Cardiovascular Electrophysiology, 2019, 30, 668-674.	0.8	98
45	Prediction and Management of Recurrences after Catheter Ablation in Atrial Fibrillation and Heart Failure. Cardiology Clinics, 2019, 37, 221-230.	0.9	4
46	Generalizability of the FOURIER trial to routine clinical care: Do trial participants represent patients in everyday practice?. American Heart Journal, 2019, 209, 54-62.	1.2	6
47	Risk of cardiovascular events and incident atrial fibrillation in patients without prior atrial fibrillation: Implications for expanding the indications for anticoagulation. American Heart Journal, 2018, 199, 137-143.	1.2	4
48	Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure. Circulation: Heart Failure, 2018, 11, e004302.	1.6	68
49	Association of Psoriasis With Comorbidity Development in Children With Psoriasis. JAMA Dermatology, 2018, 154, 286.	2.0	60
50	To teach an old dog new tricks: The limits of CHA₂DS₂-VASc in patients with atrial fibrillation and cancer. European Journal of Preventive Cardiology, 2018, 25, 994-995.	0.8	4
51	Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges. Korean Circulation Journal, 2018, 48, 873.	0.7	10
52	Association of Surgical Left Atrial Appendage Occlusion With Subsequent Stroke and Mortality Among Patients Undergoing Cardiac Surgery. JAMA - Journal of the American Medical Association, 2018, 319, 2116.	3.8	114
53	Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation, 2018, 138, 1519-1529.	1.6	359
54	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease Other Than Significant Mitral Stenosis and Mechanical Valves. Circulation, 2017, 135, 714-716.	1.6	42

#	Article	IF	Citations
55	Nonâ€“Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. Journal of the American College of Cardiology, 2017, 69, 2779-2790.	1.2	398
56	Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Gastroenterology, 2017, 152, 1014-1022.e1.	0.6	166
57	Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making. International Journal of Cardiology, 2017, 245, 174-177.	0.8	8
58	Comparison of the CHA 2 DS 2 -VASc, CHADS 2 , HAS-BLED, ORBIT, and ATRIA Risk Scores in Predicting Nonâ€“Vitamin K Antagonist Oral Anticoagulants-Associated Bleeding in Patients With Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 1549-1556.	0.7	64
59	Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 70, 2621-2632.	1.2	198
60	Medical therapies for heavy menstrual bleeding in women with uterine fibroids: a retrospective analysis of a large commercially insured population in the <scp>USA</scp>. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 322-330.	1.1	20
61	Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006â€“2013. Diabetes Care, 2017, 40, 468-475.	4.3	249
62	Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment. BMJ: British Medical Journal, 2017, 356, i6865.	2.4	129
63	Reply. Journal of the American College of Cardiology, 2017, 70, 2734-2735.	1.2	3
64	Ischemic Stroke or Systemic Embolism After Transseptal Ablation of Arrhythmias in Patients With Cardiac Implantable Electronic Devices. Journal of the American Heart Association, 2016, 5, e003163.	1.6	7
65	Association Between Patient Characteristics and Treatment Procedure Among Patients With Uterine Leiomyomas. Obstetrics and Gynecology, 2016, 127, 67-77.	1.2	35
66	Incidence and Early Outcomes of Heart Failure in Commercially Insured and Medicare Advantage Patients, 2006 to 2014. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 332-337.	0.9	14
67	Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest, 2016, 150, 1302-1312.	0.4	210
68	Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes. JAMA Internal Medicine, 2016, 176, 969.	2.6	115
69	Chronic Disease Risks From Exposure to Long-Hour Work Schedules Over a 32-Year Period. Journal of Occupational and Environmental Medicine, 2016, 58, 861-867.	0.9	20
70	Stroke and Bleeding Risks in NOAC- and Warfarin-Treated Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation. Journal of the American College of Cardiology, 2016, 67, 3020-3021.	1.2	47
71	Dabigatran Versus Warfarin in Relation to Renal Function in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2016, 68, 129-131.	1.2	12
72	Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Journal of the American Heart Association, 2016, 5, .	1.6	334

#	Article	IF	Citations
73	Pacemaker implantation after catheter ablation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2016, 45, 99-105.	0.6	8
74	Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. International Journal of Cardiology, 2016, 209, 181-183.	0.8	35
75	Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. Journal of the American Heart Association, 2016, 5, .	1.6	341
76	Trends and predictors of repeat catheter ablation for atrial fibrillation. American Heart Journal, 2016, 171, 48-55.	1.2	41
77	Does time pressure create barriers for people to receive preventive health services?. Preventive Medicine, 2015, 74, 55-58.	1.6	14
78	Association of Worksite Wellness Center Attendance With Weight Loss and Health Care Cost Savings. Journal of Occupational and Environmental Medicine, 2015, 57, 229-234.	0.9	7
79	Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation. Journal of the American Heart Association, 2015, 4, .	1.6	52
80	A novel method for estimating the effects of job conditions on asthma and chronic lung disease. Journal of Asthma, 2014, 51, 799-807.	0.9	7
81	Using O*NET to estimate the association between work exposures and chronic diseases. American Journal of Industrial Medicine, 2014, 57, 1022-1031.	1.0	22